Basilea Pharmaceutica Expands Pipeline with New Antibiotic License

Basilea Pharmaceutica ( (CH:BSLN) ) just unveiled an announcement.

Basilea Pharmaceutica has entered into an exclusive license agreement with Venatorx Pharmaceuticals to acquire worldwide rights to Ceftibuten-Ledaborbactam Etzadroxil, an oral antibiotic combination targeting complicated urinary tract infections (cUTI). This agreement is expected to enhance Basilea’s product pipeline and support its strategy for sustainable revenue growth by addressing the significant need for effective oral treatments for cUTI caused by multi-resistant bacteria. The transaction involves upfront and milestone payments, with potential royalties for Venatorx, and is projected to increase Basilea’s R&D expenses by CHF 15 million in 2025.

The most recent analyst rating on (CH:BSLN) stock is a Buy with a CHF95.00 price target. To see the full list of analyst forecasts on Basilea Pharmaceutica stock, see the CH:BSLN Stock Forecast page.

More about Basilea Pharmaceutica

Basilea Pharmaceutica AG is a Swiss biopharmaceutical company focused on discovering, developing, and marketing innovative drugs to treat severe infections caused by bacteria or fungi. The company has successfully launched Cresemba and Zevtera for hospital use and maintains a portfolio of preclinical and clinical anti-infective programs.

Average Trading Volume: 41,678

Technical Sentiment Signal: Strong Buy

Current Market Cap: CHF629.7M

For detailed information about BSLN stock, go to TipRanks’ Stock Analysis page.